文献速递肾小球疾病慢性肾脏病

小鼠肾病综合征升高FGF23并导致心脏肥大,不依赖高磷血症

Nephrotic syndrome in mice elevates FGF23 levels and leads to cardiac hypertrophy in the absence of hyperphosphatemia.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

研究采用足细胞特异性诱导表达NFATc1nuc突变的小鼠模型,1周即出现肾病综合征样表型。1周时小鼠出现蛋白尿、高脂血症、血清FGF23升高及细胞水平心脏肥大和心功能下降,但无高磷血症和骨FGF23表达增加。心脏局部FGF23升高,游离脂肪酸可在体外诱导心肌细胞表达FGF23并导致肥大。长期表达则进展为CKD样表型伴高磷血症、心脏肥大纤维化及寿命缩短。

要点

  • 肾病综合征小鼠1周出现蛋白尿、高脂血症、血清FGF23升高和细胞水平心脏肥大。
  • 此阶段无高磷血症及骨FGF23表达增加,心脏局部FGF23升高。
  • 游离脂肪酸可诱导心肌细胞表达FGF23并导致肥大,提示高脂血症驱动心脏损害。

核心结论

  • 肾病综合征小鼠中FGF23升高可不依赖高磷血症,心脏局部FGF23可能由高脂血症诱导并驱动心脏肥大。
  • NFATc1nuc小鼠可作为肾病综合征进展至CKD伴病理性心脏重构的模型。

研究设计与样本

  • 采用可诱导的足细胞特异性过表达组成性活化NFATc1突变体(NFATc1nuc)小鼠模型。
  • 在蛋白尿发生1周和3个月后分析血清磷酸盐和脂质代谢及心脏表型。

主要发现

  • 1周时小鼠出现蛋白尿、高脂血症、血清FGF23升高,以及细胞水平心脏肥大和心功能下降,但心脏质量或纤维化无显著增加。
  • NFATc1nuc小鼠血清磷酸盐水平未升高,骨FGF23表达也未增加,但心脏FGF23升高。
  • 体外研究显示游离脂肪酸诱导心肌细胞表达FGF23并导致肥大。
  • 长期NFATc1nuc表达的小鼠转变为CKD样表型,伴高磷血症、FGF23进一步升高、心脏肥大和纤维化及寿命缩短。

临床怎么用

  • 肾病综合征患者心脏损害评估时,除传统因素外可关注FGF23及脂质代谢。
  • 未来或可探索靶向心脏局部FGF23通路防治肾病综合征相关心脏肥大。

局限性

  • 结果为小鼠模型和体外实验,向人类肾病综合征外推需谨慎。
  • 原文未报告样本量、具体统计值和置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: Patients with nephrotic syndrome develop albuminuria, hyperlipidemia, and heart failure, but the pathomechanisms underlying this interconnection are unclear. We previously found that fibroblast growth factor 23 (FGF23) promotes cardiac hypertrophy in animal models of chronic kidney disease (CKD). Since patients with nephrotic syndrome have elevated FGF23, we hypothesized that FGF23 also contributes to heart damage in nephrotic syndrome. METHODS: We previously developed a mouse model with the inducible and podocyte-specific overexpression of a constitutively active NFATc1 mutant variant (NFATc1nuc), which within 1 week develops a nephrotic syndrome-like phenotype. Here, we conducted serological analyses of phosphate and lipid metabolism, and we studied the cardiac phenotype after 1 week and 3 months of albuminuria. RESULTS: After 1 week, mice presented with albuminuria, hyperlipidemia, and elevated serum FGF23 levels, as well as reductions in cardiac function and cardiac hypertrophy on a cellular level without significant increases in cardiac mass or fibrosis. Under physiologic conditions and in CKD, elevations in systemic phosphate levels, also called hyperphosphatemia, induce FGF23 production in the bone. However, in NFATc1nuc mice we could detect neither increases in serum phosphate levels nor in FGF23 expression in the bone. Instead, nephrotic mice had FGF23 elevations in the heart, and our in vitro studies showed that free fatty acids induced FGF23 expression in cardiac myocytes resulting in hypertrophy. We also found that mice with prolonged NFATc1nuc expression transition into a CKD-like phenotype with hyperphosphatemia and further FGF23 elevations, as well as cardiac hypertrophy and fibrosis and a reduced lifespan. CONCLUSION: Our study suggests that NFATc1nuc mice serve as a model of nephrotic syndrome that progresses to CKD with pathologic cardiac remodeling. Our findings indicate that hyperlipidemia might contribute to heart failure in nephrotic syndrome by inducing FGF23 expression in the heart, which then drives cardiac hypertrophy.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Fajol A, Li Q, Thomas SM, et al. Nephrotic syndrome in mice elevates FGF23 levels and leads to cardiac hypertrophy in the absence of hyperphosphatemia. Nephrol Dial Transplant. 2026. PMID: 41427917. doi:10.1093/ndt/gfaf272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。